CXCR4 Human shRNA Lentiviral Particle (Locus ID 7852)
CAT#: TL313630V
CXCR4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
Need custom lentivirus service?
Get a free quote
CNY 11,400.00
货期*
详询
规格
Cited in 4 publications. |
经常一起买 (3)
Specifications
Product Data | |
Product Name | CXCR4 Human shRNA Lentiviral Particle (Locus ID 7852) |
Locus ID | 7852 |
Synonyms | CD184; D2S201E; FB22; HM89; HSY3RR; LAP-3; LAP3; LCR1; LESTR; NPY3R; NPYR; NPYRL; NPYY3R; WHIM; WHIMS |
Vector | pGFP-C-shLenti |
Format | Lentiviral particles |
RefSeq | NM_001008540, NM_003467, NM_001348056, NM_001348059, NM_001348060, NM_003467.1, NM_003467.2, NM_001008540.1, NM_001008540.2, BC020968, BC020968.2, NM_003467.3 |
Summary | This gene encodes a CXC chemokine receptor specific for stromal cell-derived factor-1. The protein has 7 transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (4)
The use of this RNAi has been cited in the following citations: |
---|
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
,null,
Breast Cancer Research : BCR
,PubMed ID 37280713
[CXCR4]
|
Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma.
,null,
Cancer research
,PubMed ID 29735547
[CXCR4]
|
EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma
,null,
Nature Communications
,PubMed ID 26404566
[CXCR4]
|
CXCR4 Suppression Attenuates EGFRvIII-Mediated Invasion and Induces p38 MAPK-Dependent Protein Trafficking and Degradation of EGFRvIII in Breast Cancer Cells
,null,
Cancer letters
,PubMed ID 21454012
[CXCR4]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...